Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:25 AM
Ignite Modification Date: 2025-12-25 @ 2:25 AM
NCT ID: NCT06064734
Eligibility Criteria: Inclusion Criteria: 1. Age 18-80 years, gender is not limited; 2. Acute ischemic stroke of anterior circulation was diagnosed clinically 3. mRS 0-1 score before onset; 4. 6 ≤ NIHSS ≤25 at randomization; 5. Within 48 hours of stroke onset; 6. No thrombolysis therapy or thrombectomy is planned; 7. Obtain informed consent signed by the patient himself or by his legal authorized representative. Exclusion Criteria: 1. TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc. 2. Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders; 3. Midline displacement and brain parenchymal mass effect seen in head CT and other images; 4. Head CT or MRI showed bilateral acute cerebral infarction and involved insular infarction; 5. Evidence of acute intracranial hemorrhage; 6. A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease; 7. After blood pressure control, the systolic blood pressure was still ≥180 mmHg or the diastolic blood pressure was ≥110 mmHg; 8. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated glomerular filtration rate (EGFR) \< 60 mL/min; 9. Patients during pregnancy or lactation and within 90 days of planned pregnancy; 10. Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up; 11. Patients with malignancy or severe systemic disease and expected survival of less than 90 days; 12. Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 80 Years
Study: NCT06064734
Study Brief:
Protocol Section: NCT06064734